CHRS earnings: a negative outcome, -9.3%

On May 5, 2022, Coherus Oncology, Inc. reached its earnings. The result was a negative outcome, and the stock moved -9.3% in the window around the event. It had already run -23.1% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.